Market Overview
The Global Age-related Vision Dysfunction Drugs Market size was valued at approximately US$ 4.40 billion in 2025 and is forecast to reach approximately US$ 7.91 billion by 2035, growing at a CAGR of 6.03% during the forecast period 2026-2035.
Age-related vision dysfunctions include presbyopia, cataracts, age-related macular degeneration, glaucoma, diabetic retinopathy, dry eye syndrome, and others. These conditions may require specific pharmacological interventions to address their characteristics and symptoms.
There are several pharmacological options available for managing these conditions. Anti-VEGF drugs are used to combat abnormal blood vessel growth in the retina, often seen in conditions such as wet AMD and diabetic macular edema. Prostaglandin analogs can help reduce intraocular pressure, benefiting those with glaucoma by improving the outflow of aqueous humor. Beta-blockers lower intraocular pressure by reducing the production of aqueous humor, while Alpha agonists regulate pressure by modulating both production and outflow. Carbonic anhydrase inhibitors inhibit the production of aqueous humor, effectively reducing intraocular pressure.
In addition, lubricating eye drops, commonly referred to as artificial tears, provide relief from dry eye symptoms associated with age-related vision dysfunction. These drops offer essential lubrication and moisture to the eyes, playing a crucial role in managing the diverse range of age-related vision conditions. The ultimate goal is to enhance visual comfort and preserve eye health.
Market Scope
| Metrics | Details |
| CAGR | 6.03% |
| Market Size Available for Years | 2025-2035 |
| Market Estimation Forecast Period | 2026-2035 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Dysfunction Type, Drug Class, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers and Restraints
The increasing collaborations among market players for age-related vision drugs are expected to drive market growth.
On June 28, 2023, Caeregen Therapeutics, a company specializing in regenerative medicine therapeutics, and Wacker Biotech, a contract development and manufacturing organization (CDMO), will be working together starting June 28, 2023. Their collaboration will focus on the development and production of a new regenerative therapeutic called CTR-107 (Noregen), which aims to treat vision loss related to retinal conditions. As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will be producing the drug substance at its Halle, Germany facility. They will also complete the clinical trial drug product production at their Amsterdam, Netherlands location, to support the Phase I/II clinical study initiation that is planned for 2024.
Similarly, on February 27, 2023, EyePoint Pharmaceuticals, Inc. and Rallybio Corporation collaborated on a research effort. The two companies are committed to developing and commercializing therapies that improve the lives of patients with severe eye disorders and rare diseases, respectively. The partnership aims to evaluate the sustained delivery of Rallybio's inhibitor of complement component 5 (C5) using EyePoint's proprietary Durasert technology for sustained intraocular drug delivery. The initial focus of this collaboration is geographic atrophy, an advanced form of age-related macular degeneration that causes irreversible vision loss.
Likewise, on March 29, 2023, Théa Open Innovation (“TOI”), a sister company of ophthalmic specialty pharmaceutical company Laboratoires Théa, signed a licensing agreement with Galimedix Therapeutics. Galimedix is a biotechnology company that focuses on addressing the causes of neurodegenerative diseases of the eye and central nervous system. As per the agreement, TOI has been granted exclusive rights to develop and commercialize GAL-101, which is Galimedix's primary disease-modifying compound. This license covers the topical and oral treatment of dry age-related macular degeneration (AMD), glaucoma, and other ophthalmic indications that have a high unmet medical need. The license is valid in Europe, the Americas, the Middle East, and Africa.
Therefore, collaboration among market players can drive growth for drugs targeting age-related vision dysfunction. It fosters innovation, streamlines research and development, and expedites the introduction of new and more effective medications. Furthermore, the increasing clinical trials, product launches, and FDA approvals are the factors expected to drive the market over the forecast period.
Restraint:
High development costs, side effects, safety concerns, and generic competition are the factors expected to hamper the market over the forecast period.
Segment Analysis
The global age-related vision dysfunction drugs market is segmented based on dysfunction type, drug class, distribution channel, and region.
The presbyopia from the dysfunction type segment accounted for approximately 36.5% of the age-related vision dysfunction drugs market share
Presbyopia is a vision condition that often affects people as they age, making it difficult to see nearby objects. It usually becomes noticeable around age 40 and worsens over time. Presbyopia is caused by changes in the eye's natural lens and surrounding muscles, which make focusing on nearby objects more challenging.
Moreover, the increasing prevalence of presbyopia, the rising geriatric population, the increasing clinical trials, and FDA approvals are the factors expected to drive the segment over the forecast period.
For instance, according to data released by the United Nations in April 2022, the current global population is estimated to be 7.9 billion people. In 2015, it was found that around 1.8 billion individuals had presbyopia, a condition where the eyes gradually lose the ability to focus on nearby objects, and this number was projected to increase to 2.1 billion by 2020. This means that approximately 26% of the world's population currently has presbyopia. In the United States, the prevalence of presbyopia among adults aged 45 years and older ranges from 83.0% to 88.9%, and it was estimated that there were a total of 123 million individuals with presbyopia in the country in 2020.
Moreover, out of the 1.8 billion individuals around the world who suffer from presbyopia, an estimated 826 million experience near-visual impairment due to insufficient or inadequate near-vision correction. People living in high-income countries are more likely to have access to near vision correction as they have better health expenditure and access, while those in lower-income countries have less access. The majority of uncorrected presbyopia cases occur in developing and low-resource countries, where up to 94% of the population may be under or uncorrected.
Additionally, on March 30, 2023, the FDA approved a new dosing option for VUITY, a pilocarpine HCl ophthalmic solution of 1.25%, which is used to treat presbyopia in adults. This condition is commonly known as age-related blurry near vision. The new twice-daily dosing option can extend the effect of VUITY for up to 9 hours. The approval is based on the results of the Phase 3 VIRGO trial, which included 230 participants aged 40 to 55 years old with presbyopia. They were randomly given either pilocarpine HCl ophthalmic solution 1.25% or a placebo (vehicle alone) and received 1 drop in each eye twice daily, with each dose administered 6 hours apart, for 14 days.
Furthermore, Lenz Therapeutics, a biopharmaceutical company secured $83.5 million through its Series B financing round. This round was oversubscribed, and new investor Sectoral Asset Management led the financing alongside Alpha Wave Ventures and Point 72.
In addition, RA Capital Management, Versant Ventures, RTW Investments, and other existing investors also participated in the round. Lenz Therapeutics' lead late clinical-stage programs, Plate Number 1 (aceclidine) and Plate Number 2 (aceclidine and brimonidine), offer promising potential as the best-in-class therapies for presbyopia. Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.
Geographical Analysis
North America accounted for approximately 40.1% of the market share in 2022
North America is expected to hold the largest market share owing to the increasing FDA approvals, increasing prevalence of vision loss, and rising clinical trials by market players. For instance, on August 5, 2023, the U.S. Food and Drug Administration (FDA) approved Astellas Pharma Inc.'s IZERVAY (avacincaptad pegol intravitreal solution) for treating geographic atrophy (GA) that results from age-related macular degeneration (AMD). IZERVAY, which is a complement C5 inhibitor, is the sole GA treatment that has been approved and has shown a statistically significant reduction (p<0.01) in the progression rate of GA at the 12-month primary endpoint across two Phase 3 clinical trials.
Similarly, on January 28, 2022, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved Vabysmo (faricimab-svoa) to be used in treating wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME). These two conditions are responsible for a significant amount of vision loss among adults in the United States.
Likewise, on May 18, 2023, Bausch + Lomb Corporation and Novaliq GmbH received FDA approval for MIEBO, an ophthalmic solution that treats dry eye disease (DED) by targeting tear evaporation. As a global eye health company, Bausch + Lomb is dedicated to helping people see better to live better. Novaliq is a biopharmaceutical company that focuses on developing first- and best-in-class ocular therapeutics. MIEBO is the first and only FDA-approved treatment that targets the signs and symptoms of DED caused by tear evaporation.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the market for drugs related to age-related vision dysfunction. The disruption and delay of non-essential healthcare services during the pandemic, including routine eye exams and non-urgent eye care, has resulted in delayed diagnoses and treatments for age-related vision dysfunction, which has affected the demand for related drugs.
Patients have been avoiding in-person eye exams and treatment due to COVID-19 concerns, potentially worsening their conditions. Additionally, clinical trials related to new drugs or treatments for age-related vision dysfunction may have been postponed or halted during the pandemic, which has impacted the development of new therapies.
Many medical resources and research have been redirected towards studying and combating COVID-19, which has caused a temporary delay in the development of new technologies and medications for age-related vision dysfunction. As a result, the global market for drugs treating age-related vision dysfunction has been moderately impacted by COVID-19.
Competitive Landscape
The major global players in the age-related vision dysfunction drugs market include Genentech, Inc., Regeneron Pharmaceuticals Inc., Bayer AG, Allergan Inc., Viatris Inc., Novartis AG, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, and Eyenovia, Inc. among others.
Key Development
FDA approval of LYTENAVA: In July 2026, the U.S. FDA approved Outlook Therapeutics' LYTENAVA (bevacizumab-vikg) for neovascular or wet age-related macular degeneration. The product is an ophthalmic formulation administered by intravitreal injection.
- Commercial launch preparations: Following the approval, Outlook Therapeutics advanced its U.S. launch plans, including payer engagement, reimbursement strategy, commercial supply and market-access preparations, with the launch planned before the end of 2026.
- Long-term wet AMD gene-therapy data: REGENXBIO reported five-year follow-up data for investigational surabgene lomparvovec (sura-vec) in wet AMD in July 2026, while pivotal-study topline data were expected in Q4 2026.
- Extended-treatment evidence: Roche reported two-year SALWEEN study results for Vabysmo (faricimab) in polypoidal choroidal vasculopathy, a subtype of neovascular AMD. At year two, 61% of patients were assigned to a 20-week treatment interval.
- Real-world treatment evidence: Roche also presented 2026 data from the VOYAGER study showing retinal drying and improved retinal anatomy among nAMD patients treated with Vabysmo in real-world clinical practice.
Why Purchase the Report?
- To visualize the global age-related vision dysfunction drugs market segmentation based on dysfunction type, drug class, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of age-related vision dysfunction drugs market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
